



Sanofi Pasteur's information on Fav-Afrique®

“In 2010 Sanofi Pasteur ceased production of Fav-Afrique® anti-venom immunoglobulins in a context where existing emerging countries producers were supplying the large majority of the global demand and Sanofi contributed just a very limited fraction of the total demand. Since 2006, products in competition with Fav-Afrique®, whose production costs Sanofi Pasteur cannot match, have expanded in Africa and progressively replaced Fav-Afrique®, leading to a six-fold decrease in demand for this product.

Confronted with this steep drop in orders and a lack of visibility on future demand evolution, Sanofi Pasteur raised the awareness of key health authorities, including the World Health Organization at supra-national level, market stakeholders at the international level, and key opinion leaders around the anti-venoms market conditions, and in particular those affecting Fav-Afrique®. Sanofi Pasteur has significantly contributed with the World Health Organization to publish guidelines on the production and control of anti-venom immunoglobulins against snakebites to ensure quality and efficacy standardization, whatever their origin, and to facilitate production capacities ramp up for countries facing this public health issue.

Sanofi Pasteur regrets the worldwide situation with respect to the supply of anti-venom immunoglobulins and is studying options that would enable the transfer of know-how to other biologicals producers who would be willing to take over the production. Sanofi Pasteur is looking for partners able to deliver the right quality and supply sustainability of product. The process will depend on the ability of the prospective takeover company to rapidly resume production.”